Last reviewed 2026-04-23 · How we verify

Matching Placebo SC

This is a placebo control formulation used in clinical trials to match the subcutaneous administration route of an active investigational drug.

At a glance

Mechanism of action

Matching placebos are inert formulations designed to be indistinguishable from the active drug in appearance, administration route, and frequency. They serve as the control arm in blinded clinical trials to isolate the true therapeutic effect of the active agent from placebo response and other trial-related factors.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis (PHASE2)
• A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE) (PHASE3)
• A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus (PHASE2, PHASE3)
• A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition (PHASE3)
• MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
• A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease (PHASE2, PHASE3)
• A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013) (PHASE2)
• Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.